Your Cart ( 2 Items )

• Effect of Infliximab on Health-Related Quality of Life and Disease Activity by Body Region in Patients With Moderate-to-Severe Psoriasis and Inadequate Response to Etanercept: Results from the PSUNRISE Trial
  August 2013 | Volume 12 | Issue 8 | Original Article | 874 | Copyright © August 2013
  Robert E. Kalb MD,^a Andrew Blauvelt MD,^b Howard L. Sofen MD,^c Marc Chevrier MD,^d David Amato DO,^d
  Stephen Calabro MS,^d Jim Wang PhD,^e Brad Schenkel MS,^f and Alice B. Gottlieb MD PhD^g
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs
• New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
  August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
  Hemalatha Naidu MD^a, Priyanka Karagaiah MD^b, Anant Patil MD^c, Paul S. Yamauchi MD^d,e, Leon H. Kircik MD^f,g,h,i,j, Stephan Grabbe MD^k, Mohamad Goldust MD^l
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs